UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

Clinical cancer research, 2014-04, Vol.20 (8), p.2092-2103

2014

Link zum Volltext

Verfügbarkeit prüfen

The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias

Cells (Basel, Switzerland), 2020-02, Vol.9 (3), p.544

2020

Link zum Volltext

Verfügbarkeit prüfen

Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia

Frontiers in oncology, 2016-04, Vol.6, p.78-78

2016

Link zum Volltext

Verfügbarkeit prüfen

MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia

Oncotarget, 2017-08, Vol.8 (33), p.53989-54003

2017

Link zum Volltext

Verfügbarkeit prüfen

A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia

Blood cancer journal (New York), 2020-01, Vol.10 (1), p.3-3, Article 3

2020

Link zum Volltext

Verfügbarkeit prüfen

Small extracellular vesicles modulated by αVβ3 integrin induce neuroendocrine differentiation in recipient cancer cells

Journal of extracellular vesicles, 2020-05, Vol.9 (1), p.1761072-n/a

2020

Link zum Volltext

Verfügbarkeit prüfen

CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia

Haematologica (Roma), 2015-05, Vol.100 (5), p.e183

2015

Link zum Volltext

Verfügbarkeit prüfen

Data mining analysis of the PP2A cell cycle axis in mesothelioma patients

Journal of cellular physiology, 2020-06, Vol.235 (6), p.5284-5292

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 107: Data mining analysis of the PP2A-cell cycle axis in breast and prostate cancer patients

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.107-107

2020

Link zum Volltext

Verfügbarkeit prüfen

The Chromatin Assembly Factor Complex 1 (CAF1) and 5-Azacytidine (5-AzaC) Affect Cell Motility in Src-transformed Human Epithelial Cells

The Journal of biological chemistry, 2017-01, Vol.292 (1), p.172-184

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P231: Multigenomic characterization of context-dependent alternative splicing in normal and neoplastic cells

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P231-P231

2021

Link zum Volltext

Verfügbarkeit prüfen

A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity

Cancer letters, 2020-01, Vol.468, p.1-13

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 6690: Monitoring response and resistance to EGFR inhibition with circulating tumor DNA in a non-small cell lung cancer patient-derived xenograft

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.6690-6690

2023

Link zum Volltext

Verfügbarkeit prüfen

RUNX1 and GATA2 Regulate the Expression of the SET Oncogene in Acute Myeloid Leukemia

Blood, 2014-12, Vol.124 (21), p.879-879

2014

Link zum Volltext

Verfügbarkeit prüfen

GATA2 exosomal mRNA: A novel urine biomarker for the diagnosis of clinically significant prostate cancer

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.18-18

2019

Link zum Volltext

Verfügbarkeit prüfen

Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia

Oncotarget, 2016-12, Vol.7 (51), p.84214-84227

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3928: The pan-CLK/DYRK inhibitor cirtuvivint selectively disrupts alternative splicing and has broad anti-tumor activity in preclinical models

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3928-3928

2022

Link zum Volltext

Verfügbarkeit prüfen

Inactivation of NF-κB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells

Breast cancer research and treatment, 2008-11, Vol.112 (1), p.53-62

2008

Link zum Volltext

Verfügbarkeit prüfen

MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia

Oncotarget, 2017-08, Vol.8 (33), p.53989-54003

2017

Link zum Volltext

Verfügbarkeit prüfen

New insights on the transcriptional regulation of CD69 gene through a potent enhancer located in the conserved non-coding sequence 2

Molecular immunology, 2015-08, Vol.66 (2), p.171-179

2015

Link zum Volltext

Verfügbarkeit prüfen

Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcome drug resistance in myeloid leukemia

Clinical cancer research, 2014-01, Vol.20 (8), p.2092-2103

2014

Link zum Volltext

Verfügbarkeit prüfen

Reactivating PP2A by FTY720-Loaded Lipid Nanoparticles, a Novel Therapeutic Strategy in Acute Myeloid Leukemia

Blood, 2012-11, Vol.120 (21), p.1511-1511

2012

Link zum Volltext

Verfügbarkeit prüfen

Inactivation of NF-IoB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells

Breast cancer research and treatment, 2008-11, Vol.112 (1), p.53

2008

Link zum Volltext

Verfügbarkeit prüfen

Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells

Breast cancer research and treatment, 2008-11, Vol.112 (1), p.53-62

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(28)
Buchkapitel
(1)

Sprache

Englisch
(29)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Breast Cancer Research And Treatment
(4)
Cancer Research
(3)
Oncotarget
(3)
Blood
(2)
Clinical Cancer Research
(2)
Blood Cancer Journal
(1)
Cancer Letters
(1)
Cell
(1)
Cells
(1)
Frontiers In Oncology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias

Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia

MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia

A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia

Small extracellular vesicles modulated by αVβ3 integrin induce neuroendocrine differentiation in recipient cancer cells

CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia

Data mining analysis of the PP2A cell cycle axis in mesothelioma patients

Abstract 107: Data mining analysis of the PP2A-cell cycle axis in breast and prostate cancer patients

Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import

The Chromatin Assembly Factor Complex 1 (CAF1) and 5-Azacytidine (5-AzaC) Affect Cell Motility in Src-transformed Human Epithelial Cells

Abstract P231: Multigenomic characterization of context-dependent alternative splicing in normal and neoplastic cells

A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity

Abstract 6690: Monitoring response and resistance to EGFR inhibition with circulating tumor DNA in a non-small cell lung cancer patient-derived xenograft

RUNX1 and GATA2 Regulate the Expression of the SET Oncogene in Acute Myeloid Leukemia

GATA2 exosomal mRNA: A novel urine biomarker for the diagnosis of clinically significant prostate cancer

Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia

Abstract 3928: The pan-CLK/DYRK inhibitor cirtuvivint selectively disrupts alternative splicing and has broad anti-tumor activity in preclinical models

Inactivation of NF-κB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells

MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia

New insights on the transcriptional regulation of CD69 gene through a potent enhancer located in the conserved non-coding sequence 2

Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcome drug resistance in myeloid leukemia

Reactivating PP2A by FTY720-Loaded Lipid Nanoparticles, a Novel Therapeutic Strategy in Acute Myeloid Leukemia

Inactivation of NF-IoB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells

Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells

Suchergebnisse filtern